[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Tolvaptan.]
[J01GA01, streptomycin, Tolvaptan may increase the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tolvaptan.]
[A02BX02, sucralfate, Tolvaptan may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Tolvaptan may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, Tolvaptan may increase the excretion rate of Sulfadiazine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC01, sulfamethoxazole, The metabolism of Tolvaptan can be decreased when combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The metabolism of Tolvaptan can be increased when combined with Sulfinpyrazone.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Tolvaptan.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Azapropazone.]
[L02BA01, tamoxifen, The serum concentration of Tolvaptan can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Tolvaptan may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB02, teniposide, The metabolism of Tolvaptan can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Tolvaptan may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE07, dabigatran etexilate, Tolvaptan may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, The metabolism of Tolvaptan can be increased when combined with Testosterone.]
[S03AA02, tetracycline, The metabolism of Tolvaptan can be decreased when combined with Tetracycline.]
[P02CA02, thiabendazole, Tolvaptan may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Tolvaptan may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE06, moxisylyte, Tolvaptan may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Tolvaptan may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Tolvaptan may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Tolvaptan may increase the excretion rate of Timolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB02, tinidazole, Tolvaptan may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Tolvaptan may increase the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB05, tolazamide, Tolvaptan may increase the excretion rate of Tolazamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CA01, tolbutamide, Tolvaptan may increase the excretion rate of Tolbutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Tolvaptan.]
[N02AX02, tramadol, Tolvaptan may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX05, trazodone, The serum concentration of Tolvaptan can be decreased when it is combined with Trazodone.]
[S01BA05, triamcinolone, The metabolism of Tolvaptan can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tolvaptan.]
[N05CD05, triazolam, Tolvaptan may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Tolvaptan may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, Tolvaptan may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA07, mometasone, The metabolism of Tolvaptan can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Tolvaptan may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC02, trimethadione, The risk or severity of hyperkalemia can be increased when Trimethadione is combined with Tolvaptan.]
[J01EA01, trimethoprim, Tolvaptan may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Tolvaptan.]
[J01FA08, troleandomycin, The metabolism of Tolvaptan can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, The metabolism of Tolvaptan can be decreased when combined with Roflumilast.]
[L01FX04, ipilimumab, Tolvaptan may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX04, vandetanib, The serum concentration of Tolvaptan can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Tolvaptan may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The serum concentration of Tolvaptan can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Tolvaptan can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Tolvaptan can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Tolvaptan can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Tolvaptan may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX21, ezogabine, Tolvaptan may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Tolvaptan may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, The serum concentration of Tolvaptan can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Tolvaptan can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Tolvaptan can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Tolvaptan can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Tolvaptan can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The serum concentration of Tolvaptan can be increased when it is combined with Vincristine.]
[B03BA01, vitamin B12, Tolvaptan may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[A11HA03, vitamin E, The metabolism of Tolvaptan can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Tolvaptan can be increased when combined with Warfarin.]
[N05AF05, zuclopenthixol, The metabolism of Tolvaptan can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Tolvaptan can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Tolvaptan can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Tolvaptan can be decreased when combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, Tolvaptan may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Tolvaptan may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The metabolism of Tolvaptan can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Tolvaptan can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Tolvaptan may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AE04, ziprasidone, The metabolism of Tolvaptan can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Tolvaptan can be decreased when combined with Drospirenone.]
[V03AC02, deferiprone, Tolvaptan may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Tolvaptan which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Tolvaptan may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Tolvaptan may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Tolvaptan may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The risk or severity of hyperkalemia can be increased when Atenolol is combined with Tolvaptan.]
[J02AC03, voriconazole, The serum concentration of Tolvaptan can be increased when it is combined with Voriconazole.]
[M01CB03, auranofin, Tolvaptan may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Tolvaptan.]
[R07AX02, ivacaftor, The serum concentration of Tolvaptan can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Tolvaptan can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, Tolvaptan may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Tolvaptan may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Tolvaptan may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Tolvaptan may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Tolvaptan may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Tolvaptan.]
[M03BX01, baclofen, Tolvaptan may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA11, lorcaserin, Tolvaptan may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, The serum concentration of Tolvaptan can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Tolvaptan can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Tolvaptan can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Tolvaptan can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Tolvaptan can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Linaclotide.]
[L01EA04, bosutinib, The metabolism of Tolvaptan can be decreased when combined with Bosutinib.]
[L01EX05, regorafenib, The serum concentration of Tolvaptan can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Tolvaptan can be increased when combined with Barbital.]
[D02BA02, octinoxate, Tolvaptan may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, The metabolism of Tolvaptan can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Tolvaptan.]
[N04BD02, rasagiline, Tolvaptan may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA13, lercanidipine, The risk or severity of hyperkalemia can be increased when Lercanidipine is combined with Tolvaptan.]
[N03AX22, perampanel, The metabolism of Tolvaptan can be increased when combined with Perampanel.]
[V09IX04, fluorodeoxyglucose F18, Tolvaptan may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[H01CB05, pasireotide, The metabolism of Tolvaptan can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Tolvaptan can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Tolvaptan may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The serum concentration of Tolvaptan can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Tolvaptan can be increased when it is combined with Apixaban.]
[A16AX08, teduglutide, Tolvaptan may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AX12, lomitapide, The serum concentration of Tolvaptan can be increased when it is combined with Lomitapide.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Bencyclane.]
[A10BH04, alogliptin, Tolvaptan may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Tolvaptan can be increased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, Tolvaptan may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Benorilate.]
[A10BK02, canagliflozin, The serum concentration of Tolvaptan can be increased when it is combined with Canagliflozin.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Tolvaptan.]
[L03AA12, ancestim, Tolvaptan may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Tolvaptan.]
[L04AA18, everolimus, The serum concentration of Tolvaptan can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Tolvaptan may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Tolvaptan can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Tolvaptan may increase the excretion rate of Benzydamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EE01, trametinib, Tolvaptan may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Tolvaptan may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EB03, afatinib, The serum concentration of Tolvaptan can be increased when it is combined with Afatinib.]
[N06AX28, levomilnacipran, Tolvaptan may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AJ03, dolutegravir, The serum concentration of Tolvaptan can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of hyperkalemia can be increased when Bepridil is combined with Tolvaptan.]
[C02KX05, riociguat, The serum concentration of Tolvaptan can be increased when it is combined with Riociguat.]
[A10BJ03, lixisenatide, Tolvaptan may increase the excretion rate of Lixisenatide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KX04, macitentan, Tolvaptan may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, Tolvaptan may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Tolvaptan may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF04, eslicarbazepine, The metabolism of Tolvaptan can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Tolvaptan can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, Tolvaptan may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Tolvaptan may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Tolvaptan.]
[N05CH03, tasimelteon, The metabolism of Tolvaptan can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Tolvaptan can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Tolvaptan can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Tolvaptan can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Tolvaptan can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Tolvaptan.]
[V03AB34, fomepizole, Tolvaptan may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC11, siltuximab, The metabolism of Tolvaptan can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Tolvaptan can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The serum concentration of Tolvaptan can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Tolvaptan can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Tolvaptan can be decreased when combined with Idelalisib.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Tolvaptan.]
[V08AA01, diatrizoic acid, Tolvaptan may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Tolvaptan may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM19, suvorexant, The serum concentration of Tolvaptan can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Tolvaptan can be increased when it is combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Tolvaptan can be increased when combined with Oritavancin.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Phenolphthalein.]
[A06AH03, naloxegol, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Naloxegol.]
[L01EX09, nintedanib, The metabolism of Tolvaptan can be decreased when combined with Nintedanib.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Bisacodyl.]
[J05AP09, dasabuvir, The serum concentration of Tolvaptan can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Tolvaptan can be decreased when combined with Olaparib.]
[B01AF03, edoxaban, Tolvaptan may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX11, mirtazapine, The metabolism of Tolvaptan can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Tolvaptan can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Tolvaptan can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Tolvaptan can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Tolvaptan.]
[J05AP07, daclatasvir, The serum concentration of Tolvaptan can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Tolvaptan can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, Tolvaptan may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP06, asunaprevir, The serum concentration of Tolvaptan can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Eluxadoline.]
[A04AD14, rolapitant, The serum concentration of Tolvaptan can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Tolvaptan can be increased when it is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, Tolvaptan may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB11, acemetacin, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, The metabolism of Tolvaptan can be decreased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Tolvaptan.]
[V03AB37, idarucizumab, Tolvaptan may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AC05, isavuconazole, The serum concentration of Tolvaptan can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Tolvaptan can be decreased when combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The metabolism of Tolvaptan can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Tolvaptan can be decreased when combined with Cobimetinib.]
[L01XG03, ixazomib, Tolvaptan may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, The serum concentration of Tolvaptan can be increased when it is combined with Selexipag.]
[M04AB05, lesinurad, The metabolism of Tolvaptan can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Tolvaptan can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Tolvaptan can be increased when it is combined with Grazoprevir.]
[N05CA05, aprobarbital, The metabolism of Tolvaptan can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Alminoprofen.]
[N03AX23, brivaracetam, Tolvaptan may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX52, venetoclax, The serum concentration of Tolvaptan can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, Tolvaptan may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02AD05, aluminum magnesium silicate, Tolvaptan may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA01, amlodipine, The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Tolvaptan.]
[N05AX17, pimavanserin, The metabolism of Tolvaptan can be decreased when combined with Pimavanserin.]
[C03CA02, bumetanide, Tolvaptan may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Tolvaptan may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA19, bupranolol, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Tolvaptan can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, Tolvaptan may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, The serum concentration of Tolvaptan can be increased when it is combined with Arsenic trioxide.]
[M02AA03, clofezone, Tolvaptan may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Butorphanol.]
[L01XK03, rucaparib, The metabolism of Tolvaptan can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Tolvaptan can be decreased when combined with Azithromycin.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Plecanatide.]
[L01EF02, ribociclib, The metabolism of Tolvaptan can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Tolvaptan.]
[A06AH05, naldemedine, Tolvaptan may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Tolvaptan may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, Tolvaptan may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, Tolvaptan may increase the hyperkalemic activities of Benazepril.]
[D05AX03, calcitriol, The metabolism of Tolvaptan can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Tolvaptan may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF06, abacavir, Tolvaptan may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The metabolism of Tolvaptan can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Tolvaptan may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB02, infliximab, The metabolism of Tolvaptan can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Tolvaptan can be decreased when combined with Midostaurin.]
[L04AC14, sarilumab, The metabolism of Tolvaptan can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, Tolvaptan may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF04, betrixaban, The serum concentration of Tolvaptan can be increased when it is combined with Betrixaban.]
[D01AC10, bifonazole, The metabolism of Tolvaptan can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, Tolvaptan may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX59, enasidenib, The serum concentration of Tolvaptan can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Tolvaptan can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Tolvaptan can be increased when it is combined with Inotuzumab ozogamicin.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Tolvaptan.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Tolvaptan.]
[C07AB07, bisoprolol, Tolvaptan may increase the excretion rate of Bisoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG03, efavirenz, The metabolism of Tolvaptan can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Bopindolol.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Canrenone.]
[R03BA02, budesonide, The metabolism of Tolvaptan can be increased when combined with Budesonide.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Tolvaptan can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Tolvaptan can be decreased when combined with Letermovir.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Tolvaptan.]
[N01BX04, capsaicin, The metabolism of Tolvaptan can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Tolvaptan can be increased when it is combined with Ertugliflozin.]
[R06AX18, acrivastine, Tolvaptan may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, Tolvaptan may increase the hyperkalemic activities of Captopril.]
[L02BB05, apalutamide, The serum concentration of Tolvaptan can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Tolvaptan can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, The serum concentration of Tolvaptan can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Tolvaptan can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Tolvaptan can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Tolvaptan can be increased when it is combined with Avatrombopag.]
[L04AA37, baricitinib, Tolvaptan may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Tolvaptan.]
[J01DD14, ceftibuten, Tolvaptan may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Tolvaptan may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB08, celiprolol, The risk or severity of hyperkalemia can be increased when Celiprolol is combined with Tolvaptan.]
[H01CC03, elagolix, The serum concentration of Tolvaptan can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Tolvaptan can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Tolvaptan may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The metabolism of Tolvaptan can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Tolvaptan can be increased when it is combined with Lusutrombopag.]
[J05AX24, tecovirimat, The metabolism of Tolvaptan can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Tolvaptan can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Tolvaptan can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Tolvaptan can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Tolvaptan can be increased when it is combined with Omadacycline.]
[S01GX12, cetirizine, Tolvaptan may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[D08AE05, chloroxylenol, Tolvaptan may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Lornoxicam.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Tolvaptan.]
[R03BB08, revefenacin, The serum concentration of Tolvaptan can be increased when it is combined with Revefenacin.]
[L01ED05, lorlatinib, The serum concentration of Tolvaptan can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Tolvaptan can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Tolvaptan may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX12, larotrectinib, The serum concentration of Tolvaptan can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The metabolism of Tolvaptan can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Tolvaptan can be increased when it is combined with Glasdegib.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Prucalopride.]
[C09AA08, cilazapril, Tolvaptan may increase the hyperkalemic activities of Cilazapril.]
[B01AC23, cilostazol, Tolvaptan may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[P02BX04, triclabendazole, The metabolism of Tolvaptan can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Tolvaptan can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Tolvaptan can be decreased when combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Tolvaptan can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Tolvaptan may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EN01, erdafitinib, The serum concentration of Tolvaptan can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Tolvaptan can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Tolvaptan can be increased when combined with Cloprednol.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Castor oil.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Tolvaptan can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Tolvaptan can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Tolvaptan can be increased when combined with Alpelisib.]
[J01DC04, cefaclor, Tolvaptan may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Tolvaptan may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BB06, darolutamide, The serum concentration of Tolvaptan can be increased when it is combined with Darolutamide.]
[J01DC05, cefotetan, Tolvaptan may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD02, ceftazidime, Tolvaptan may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD04, ceftriaxone, Tolvaptan may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ02, fedratinib, The serum concentration of Tolvaptan can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Tolvaptan can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Tolvaptan can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Tolvaptan can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Tolvaptan can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The serum concentration of Tolvaptan can be increased when it is combined with Istradefylline.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tolvaptan.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Dantron.]
[J01XX09, daptomycin, Tolvaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, The metabolism of Tolvaptan can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Tolvaptan can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Tolvaptan can be increased when combined with Deflazacort.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Tolvaptan can be increased when it is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, The serum concentration of Tolvaptan can be increased when it is combined with Lasmiditan.]
[B06AX03, voxelotor, The serum concentration of Tolvaptan can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Tolvaptan can be decreased when it is combined with Cenobamate.]
[M09AX08, golodirsen, Tolvaptan may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CD04, ubrogepant, The serum concentration of Tolvaptan can be increased when it is combined with Ubrogepant.]
[L01FX13, enfortumab vedotin, The serum concentration of Tolvaptan can be increased when it is combined with Enfortumab vedotin.]
[S01XA12, dexpanthenol, Tolvaptan may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Dezocine.]
[N05CM21, lemborexant, The serum concentration of Tolvaptan can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tolvaptan can be decreased when combined with Tazemetostat.]
[N02CD06, rimegepant, The serum concentration of Tolvaptan can be increased when it is combined with Rimegepant.]
[J05AB16, remdesivir, The metabolism of Tolvaptan can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Tolvaptan can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Tolvaptan can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Tolvaptan can be increased when it is combined with Selumetinib.]
[R02AA03, dichlorobenzyl alcohol, Tolvaptan may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Tolvaptan may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The metabolism of Tolvaptan can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Tolvaptan can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Tolvaptan can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Tolvaptan can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Tolvaptan can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Tolvaptan can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Tolvaptan which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Tolvaptan can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Tolvaptan can be increased when combined with Fluprednidene.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Droxicam.]
[L01EX19, ripretinib, The serum concentration of Tolvaptan can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, Tolvaptan may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA27, dexketoprofen, Tolvaptan may increase the excretion rate of Dexketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX22, ebastine, The metabolism of Tolvaptan can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The serum concentration of Tolvaptan can be increased when it is combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, The serum concentration of Tolvaptan can be increased when it is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Tolvaptan can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Tolvaptan may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX23, pralsetinib, The serum concentration of Tolvaptan can be increased when it is combined with Pralsetinib.]
[N05AA01, chlorpromazine, The metabolism of Tolvaptan can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Tolvaptan may increase the excretion rate of Chlorpropamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Tolvaptan may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Ethenzamide.]
[N02BA03, choline salicylate, Tolvaptan may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Vinpocetine.]
[M01AB08, etodolac, Tolvaptan may increase the excretion rate of Etodolac which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Etofenamate.]
[B06AC06, berotralstat, The serum concentration of Tolvaptan can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Tolvaptan can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Tolvaptan can be increased when it is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Tolvaptan may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AD03, voclosporin, The serum concentration of Tolvaptan can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Tolvaptan can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tolvaptan can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Tolvaptan can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Tolvaptan can be increased when it is combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Tolvaptan can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Fenbufen.]
[C01CA19, fenoldopam, Tolvaptan may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Tolvaptan may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA03, flunisolide, The metabolism of Tolvaptan can be increased when combined with Flunisolide.]
[N02BG07, flupirtine, Tolvaptan may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Tolvaptan.]
[L01EK03, tivozanib, The serum concentration of Tolvaptan can be increased when it is combined with Tivozanib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Tolvaptan can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, The metabolism of Tolvaptan can be decreased when combined with Cimetidine.]
[V08CA04, gadoteridol, Tolvaptan may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Tolvaptan.]
[L01XX73, sotorasib, The serum concentration of Tolvaptan can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Tolvaptan can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Tolvaptan can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Tolvaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB04, citalopram, The metabolism of Tolvaptan can be decreased when combined with Citalopram.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Finerenone.]
[L04AA48, belumosudil, The serum concentration of Tolvaptan can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Tolvaptan can be decreased when combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Tolvaptan can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Tolvaptan can be decreased when it is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Tolvaptan may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Tolvaptan may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Tolvaptan can be increased when it is combined with Technetium Tc-99m sestamibi.]
[V09AX06, florbetaben f-18, Tolvaptan may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA59, avacopan, The metabolism of Tolvaptan can be decreased when combined with Avacopan.]
[N06AX25, St. John's wort extract, The serum concentration of Tolvaptan can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Tolvaptan can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Tolvaptan can be increased when it is combined with Maribavir.]
[D11AH08, abrocitinib, The serum concentration of Tolvaptan can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Tolvaptan can be increased when it is combined with Clofazimine.]
[C10AB01, clofibrate, The metabolism of Tolvaptan can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Tolvaptan can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Tolvaptan may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ03, pacritinib, The serum concentration of Tolvaptan can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Tolvaptan can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, Tolvaptan may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Tolvaptan may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C01EB24, mavacamten, The serum concentration of Tolvaptan can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Tolvaptan may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AX31, lenacapavir, The metabolism of Tolvaptan can be decreased when combined with Lenacapavir.]
[L01XX77, adagrasib, The serum concentration of Tolvaptan can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The metabolism of Tolvaptan can be increased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Tolvaptan can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Tolvaptan can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Tolvaptan can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Tolvaptan can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, Tolvaptan may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA03, tropisetron, Tolvaptan may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, Tolvaptan may increase the excretion rate of Nateglinide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Imidazole salicylate.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Tolvaptan.]
[J01FA15, telithromycin, The metabolism of Tolvaptan can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Indobufen.]
[J05AB14, valganciclovir, Tolvaptan may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Tolvaptan may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Tolvaptan may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Tolvaptan may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Tolvaptan may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Tolvaptan may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Tolvaptan.]
[N02CC05, almotriptan, Tolvaptan may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Tolvaptan can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Bemiparin.]
[S01AD03, acyclovir, Tolvaptan may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, The metabolism of Tolvaptan can be decreased when combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Tolvaptan can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Tolvaptan can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Lactitol.]
[N03AX09, lamotrigine, Tolvaptan may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The metabolism of Tolvaptan can be increased when combined with Cortisone.]
[N07BC04, lofexidine, Tolvaptan may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Loxoprofen.]
[C09AA03, lisinopril, Tolvaptan may increase the hyperkalemic activities of Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Magnesium carbonate.]
[C08CA11, manidipine, The metabolism of Tolvaptan can be decreased when combined with Manidipine.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Mepindolol.]
[H02AB15, meprednisone, The metabolism of Tolvaptan can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Tolvaptan can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Tolvaptan may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Tolvaptan.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Tolvaptan.]
[N05AD03, metylperon, Tolvaptan may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA03, midecamycin, The metabolism of Tolvaptan can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, Tolvaptan may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA01, cyclophosphamide, The metabolism of Tolvaptan can be increased when combined with Cyclophosphamide.]
[S01XA18, cyclosporine, The serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.]
[N06BA07, modafinil, The metabolism of Tolvaptan can be increased when combined with Modafinil.]
[C09AA13, moexipril, Tolvaptan may increase the hyperkalemic activities of Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Tolvaptan can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Tolvaptan can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Tolvaptan can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Tolvaptan can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, Tolvaptan may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DA01, dactinomycin, The serum concentration of Tolvaptan can be increased when it is combined with Dactinomycin.]
[G03XA01, danazol, The metabolism of Tolvaptan can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Tolvaptan.]
[L01DB02, daunorubicin, The metabolism of Tolvaptan can be decreased when combined with Daunorubicin.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Tolvaptan.]
[N07BB05, nalmefene, Tolvaptan may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Potassium lactate.]
[C07AB12, nebivolol, The risk or severity of hyperkalemia can be increased when Nebivolol is combined with Tolvaptan.]
[S01GX04, nedocromil, Tolvaptan may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The metabolism of Tolvaptan can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Tolvaptan may increase the excretion rate of Nicorandil which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BB02, nilutamide, Tolvaptan may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Tolvaptan.]
[R05DA06, normethadone, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Tolvaptan may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Tolvaptan.]
[N06AA01, desipramine, The metabolism of Tolvaptan can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.]
[V04CH02, indigo carmine, Tolvaptan may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH03, ertapenem, Tolvaptan may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Aliskiren.]
[M01AE12, oxaprozin, Tolvaptan may increase the excretion rate of Oxaprozin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF02, oxcarbazepine, The metabolism of Tolvaptan can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Tolvaptan can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Tolvaptan can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Tolvaptan can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Tolvaptan may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AC01, dextromoramide, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Dextromoramide.]
[N07BC06, heroin, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Diamorphine.]
[P03AC04, permethrin, Tolvaptan may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Tolvaptan may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA08, pholcodine, Tolvaptan may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Tolvaptan.]
[J01CF01, dicloxacillin, The metabolism of Tolvaptan can be increased when combined with Dicloxacillin.]
[A03AA07, dicyclomine, Tolvaptan may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF02, didanosine, Tolvaptan may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Pinaverium.]
[L01DC04, ixabepilone, The serum concentration of Tolvaptan can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Tolvaptan can be decreased when combined with Erlotinib.]
[L02AA01, diethylstilbestrol, The metabolism of Tolvaptan can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Tolvaptan can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Tolvaptan can be increased when combined with Difluocortolone.]
[N02BA11, diflunisal, Tolvaptan may increase the excretion rate of Diflunisal which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA04, digitoxin, The serum concentration of Tolvaptan can be increased when it is combined with Digitoxin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Tolvaptan.]
[C04AE04, dihydroergocristine, The metabolism of Tolvaptan can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Tolvaptan can be decreased when combined with Dihydroergotamine.]
[N02AA03, hydromorphone, Tolvaptan may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Tolvaptan may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The metabolism of Tolvaptan can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, Tolvaptan may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Tolvaptan may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The metabolism of Tolvaptan can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Tolvaptan may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX03, dimethyl sulfoxide, The metabolism of Tolvaptan can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Proglumetacin.]
[C05CA03, diosmin, The serum concentration of Tolvaptan can be increased when it is combined with Diosmin.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, Tolvaptan may increase the hyperkalemic activities of Quinapril.]
[A03FA02, cisapride, The metabolism of Tolvaptan can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Tolvaptan may increase the hyperkalemic activities of Ramipril.]
[S01XA23, sirolimus, The serum concentration of Tolvaptan can be increased when it is combined with Sirolimus.]
[S01AX06, resorcinol, Tolvaptan may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, Tolvaptan may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA12, rifamycin SV, The serum concentration of Tolvaptan can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Tolvaptan can be increased when combined with Rifapentine.]
[R06AE09, levocetirizine, Tolvaptan may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Tolvaptan may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AD12, aprepitant, The metabolism of Tolvaptan can be decreased when combined with Aprepitant.]
[S01AA13, fusidic acid, The metabolism of Tolvaptan can be decreased when combined with Fusidic acid.]
[S02BA08, fluocinolone acetonide, The metabolism of Tolvaptan can be increased when combined with Fluocinolone acetonide.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Tolvaptan.]
[C01DA05, pentaerythritol tetranitrate, Tolvaptan may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The serum concentration of Tolvaptan can be increased when it is combined with Bortezomib.]
[J05AE07, fosamprenavir, The metabolism of Tolvaptan can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, Tolvaptan may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Tolvaptan.]
[C02KX02, ambrisentan, The serum concentration of Tolvaptan can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Tolvaptan can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Tolvaptan.]
[H05BA01, salmon calcitonin, Tolvaptan may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Tolvaptan may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA04, dopamine, Tolvaptan may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA12, doxepin, Tolvaptan may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Sennosides.]
[L01DB01, doxorubicin, The metabolism of Tolvaptan can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Tolvaptan may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA10, sibutramine, Tolvaptan may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA01, simvastatin, The serum concentration of Tolvaptan can be increased when it is combined with Simvastatin.]
[V03AG05, sodium phosphate, Tolvaptan may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Sodium sulfate.]
[C09AA11, spirapril, Tolvaptan may increase the hyperkalemic activities of Spirapril.]
[R03DA01, dyphylline, Tolvaptan may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Tolvaptan may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Tolvaptan may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The serum concentration of Tolvaptan can be increased when it is combined with Talinolol.]
[H01AA01, corticotropin, The metabolism of Tolvaptan can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, Tolvaptan may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Tolvaptan.]
[D01BA02, terbinafine, The metabolism of Tolvaptan can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Tertatolol.]
[C09AA02, enalapril, Tolvaptan may increase the hyperkalemic activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Tolvaptan may increase the excretion rate of Toloxatone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA09, atomoxetine, Tolvaptan may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, The metabolism of Tolvaptan can be increased when combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Tolvaptan can be increased when it is combined with Toremifene.]
[C09AA10, trandolapril, Tolvaptan may increase the hyperkalemic activities of Trandolapril.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Tolvaptan.]
[N06AX16, venlafaxine, Tolvaptan may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The metabolism of Tolvaptan can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Tolvaptan can be decreased when combined with Epinephrine.]
[C09AA15, zofenopril, Tolvaptan may increase the hyperkalemic activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Tolvaptan.]
[N03AX15, zonisamide, The serum concentration of Tolvaptan can be increased when it is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Tolvaptan.]
[L01XA02, carboplatin, Tolvaptan may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, Tolvaptan may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA02, ergotamine, The metabolism of Tolvaptan can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Tolvaptan may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The serum concentration of Tolvaptan can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, Tolvaptan may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Tolvaptan may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, Tolvaptan may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Tolvaptan may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, The metabolism of Tolvaptan can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Tolvaptan can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Tolvaptan can be increased when combined with Fluticasone.]
[V08CA03, gadodiamide, Tolvaptan may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD05, ibutilide, Tolvaptan may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Tolvaptan.]
[M01AC06, meloxicam, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Tolvaptan may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The serum concentration of Tolvaptan can be increased when it is combined with Etoposide.]
[L04AD02, tacrolimus, The serum concentration of Tolvaptan can be increased when it is combined with Tacrolimus.]
[R06AX11, astemizole, The metabolism of Tolvaptan can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Tolvaptan can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Tolvaptan may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Tolvaptan may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, The metabolism of Tolvaptan can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, Tolvaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA03, pravastatin, The serum concentration of Tolvaptan can be increased when it is combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, Tolvaptan may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Tolvaptan may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Tolvaptan may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Tolvaptan may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA03, albendazole, The metabolism of Tolvaptan can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of hyperkalemia can be increased when Felodipine is combined with Tolvaptan.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Tolvaptan.]
[N02AB03, fentanyl, Tolvaptan may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, Tolvaptan may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BB06, clofarabine, Tolvaptan may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Tolvaptan may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Tolvaptan may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Floctafenine.]
[J01CF05, floxacillin, The metabolism of Tolvaptan can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Tolvaptan can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, Tolvaptan may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB25, flumazenil, Tolvaptan may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Flunarizine is combined with Tolvaptan.]
[D07AC08, fluocinonide, The metabolism of Tolvaptan can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Tolvaptan can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Tolvaptan can be increased when combined with Ethanol.]
[L01BC09, floxuridine, Tolvaptan may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB03, fluoxetine, The metabolism of Tolvaptan can be decreased when combined with Fluoxetine.]
[N05CD01, flurazepam, Tolvaptan may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, Tolvaptan may increase the excretion rate of Flurbiprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Tolvaptan.]
[L02BB01, flutamide, Tolvaptan may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Tolvaptan may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Tolvaptan may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC03, tegafur, Tolvaptan may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE10, darunavir, The serum concentration of Tolvaptan can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Tolvaptan may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Tolvaptan may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Gallopamil.]
[S01AD09, ganciclovir, Tolvaptan may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, The metabolism of Tolvaptan can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, Tolvaptan may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Tolvaptan may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The metabolism of Tolvaptan can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Tolvaptan.]
[J05AG04, etravirine, The metabolism of Tolvaptan can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Tolvaptan.]
[N01AH02, alfentanil, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Tolvaptan can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Tolvaptan can be decreased when combined with Glyburide.]
[A10BB07, glipizide, Tolvaptan may increase the excretion rate of Glipizide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM18, dexmedetomidine, Tolvaptan may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Glycerin.]
[C02CA04, doxazosin, The metabolism of Tolvaptan can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The serum concentration of Tolvaptan can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of hyperkalemia can be increased when Esmolol is combined with Tolvaptan.]
[M01CB04, aurothioglucose, Tolvaptan may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Tolvaptan may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA09, fosinopril, Tolvaptan may increase the hyperkalemic activities of Fosinopril.]
[D01BA01, griseofulvin, The metabolism of Tolvaptan can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Tolvaptan may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, Tolvaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Tolvaptan.]
[N05AH04, quetiapine, Tolvaptan may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX13, idebenone, Tolvaptan may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Tolvaptan.]
[M04AA01, allopurinol, Tolvaptan may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Tolvaptan.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Magnesium citrate.]
[G03DC01, allylestrenol, The metabolism of Tolvaptan can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Tolvaptan.]
[C01CE02, milrinone, Tolvaptan may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Sodium fluorophosphate.]
[C08CA10, nilvadipine, The metabolism of Tolvaptan can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hyperkalemia can be increased when Nimesulide is combined with Tolvaptan.]
[C09AA04, perindopril, Tolvaptan may increase the hyperkalemic activities of Perindopril.]
[C02DB02, hydralazine, The metabolism of Tolvaptan can be decreased when combined with Hydralazine.]
[R05DA03, hydrocodone, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Tolvaptan can be increased when combined with Hydrocortisone.]
[B05XA17, potassium acetate, Tolvaptan may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Tolvaptan.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Tolvaptan.]
[V03AB33, hydroxocobalamin, Tolvaptan may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Tolvaptan may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA07, hetastarch, Tolvaptan may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB04, rifabutin, The metabolism of Tolvaptan can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, Tolvaptan may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA08, sodium acetate, Tolvaptan may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Sodium tartrate.]
[L01AA06, ifosfamide, The metabolism of Tolvaptan can be increased when combined with Ifosfamide.]
[N01AH03, sufentanil, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Tolvaptan may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The metabolism of Tolvaptan can be increased when combined with Paclitaxel.]
[R01AD07, tixocortol, Tolvaptan may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CE01, topotecan, Tolvaptan may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, Tolvaptan may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Tolvaptan.]
[A11HA07, inositol, Tolvaptan may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The metabolism of Tolvaptan can be decreased when combined with Milnacipran.]
[S01XA28, varenicline, Tolvaptan may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, Tolvaptan may increase the excretion rate of Sitagliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA12, alprazolam, Tolvaptan may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Tolvaptan may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA06, cerivastatin, The metabolism of Tolvaptan can be increased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of hyperkalemia can be increased when Alprenolol is combined with Tolvaptan.]
[V03AB01, ipecac, Tolvaptan may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA16, imidapril, Tolvaptan may increase the hyperkalemic activities of Imidapril.]
[J04AC01, isoniazid, The metabolism of Tolvaptan can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Tolvaptan may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[D10BA01, isotretinoin, Tolvaptan may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC07, tocilizumab, The metabolism of Tolvaptan can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Tolvaptan may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC22, prasugrel, Tolvaptan may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, The metabolism of Tolvaptan can be decreased when combined with Ketoconazole.]
[M02AA10, ketoprofen, Tolvaptan may increase the excretion rate of Ketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC03, deferasirox, The metabolism of Tolvaptan can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Tolvaptan can be increased when combined with Abatacept.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Tolvaptan.]
[C07AG01, labetalol, Tolvaptan may increase the excretion rate of Labetalol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BB01, amantadine, Tolvaptan may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Lubiprostone.]
[N03AX18, lacosamide, The metabolism of Tolvaptan can be decreased when combined with Lacosamide.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Tolvaptan can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Tolvaptan.]
[A07DA03, loperamide, The serum concentration of Tolvaptan can be increased when it is combined with Loperamide.]
[N05BA06, lorazepam, Tolvaptan may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Tolvaptan can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Tolvaptan can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Tolvaptan can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Tolvaptan may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Tolvaptan may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The metabolism of Tolvaptan can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Mannitol.]
[N06AA21, maprotiline, Tolvaptan may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Tolvaptan may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA18, meclofenamic acid, Tolvaptan may increase the excretion rate of Meclofenamic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Tolvaptan.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Frangula purshiana bark.]
[P01BC02, mefloquine, The serum concentration of Tolvaptan can be increased when it is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Tolvaptan.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Dalteparin.]
[N06DX01, memantine, Tolvaptan may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, The metabolism of Tolvaptan can be decreased when combined with Meperidine.]
[N03AA01, mephobarbital, The metabolism of Tolvaptan can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Tolvaptan may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Tolvaptan may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG01, aminoglutethimide, The metabolism of Tolvaptan can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Tolvaptan may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, The serum concentration of Tolvaptan can be increased when it is combined with Paliperidone.]
[A10BA02, metformin, Tolvaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[H01CB03, lanreotide, The metabolism of Tolvaptan can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Tolvaptan can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, Tolvaptan may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Tolvaptan may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The metabolism of Tolvaptan can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Tolvaptan may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.]
[A11HA02, pyridoxine, Tolvaptan may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Tolvaptan is combined with Ziconotide.]
[L04AX03, methotrexate, Tolvaptan may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[D05BA02, methoxsalen, Tolvaptan may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Methylcellulose.]
[C02AB01, methyldopa, Tolvaptan may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, The serum concentration of Tolvaptan can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Tolvaptan can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, The metabolism of Tolvaptan can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Tolvaptan can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Tolvaptan may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA04, methysergide, The metabolism of Tolvaptan can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, Tolvaptan may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, Tolvaptan may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Tolvaptan may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB01, metronidazole, The metabolism of Tolvaptan can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Tolvaptan can be increased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Tolvaptan can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Tolvaptan.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Parnaparin.]
[N05CD08, midazolam, The metabolism of Tolvaptan can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The serum concentration of Tolvaptan can be decreased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Tinzaparin.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Mineral oil.]
[J05AH01, zanamivir, Tolvaptan may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Valsartan.]
[J01FA11, miocamycin, The metabolism of Tolvaptan can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Tolvaptan can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, The metabolism of Tolvaptan can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Tolvaptan can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Tolvaptan may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The serum concentration of Tolvaptan can be increased when it is combined with Morphine.]
[A04AA05, palonosetron, Tolvaptan may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB05, certolizumab pegol, The metabolism of Tolvaptan can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Tolvaptan may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The metabolism of Tolvaptan can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, Tolvaptan may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA02, amobarbital, The metabolism of Tolvaptan can be increased when combined with Amobarbital.]
[G04CA04, silodosin, The serum concentration of Tolvaptan can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The metabolism of Tolvaptan can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Tolvaptan can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Tolvaptan may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA04, amoxicillin, Tolvaptan may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CF06, nafcillin, The metabolism of Tolvaptan can be increased when combined with Nafcillin.]
[N02AF02, nalbuphine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Tolvaptan can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Naltrexone.]
[L04AC03, anakinra, The metabolism of Tolvaptan can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Tolvaptan may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Tolvaptan.]
[A10BG01, troglitazone, The metabolism of Tolvaptan can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, Tolvaptan may increase the excretion rate of Duloxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BX01, tolcapone, Tolvaptan may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD02, docetaxel, The metabolism of Tolvaptan can be decreased when combined with Docetaxel.]
[N01AH06, remifentanil, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Remifentanil.]
[B01AC17, tirofiban, Tolvaptan may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA19, ampicillin, Tolvaptan may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Tolvaptan may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX23, desvenlafaxine, The metabolism of Tolvaptan can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Telmisartan.]
[J05AB11, valacyclovir, Tolvaptan may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CE01, inamrinone, Tolvaptan may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AD02, niacin, The metabolism of Tolvaptan can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Tolvaptan can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, Tolvaptan may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Tolvaptan.]
[C08CA06, nimodipine, The risk or severity of hyperkalemia can be increased when Nimodipine is combined with Tolvaptan.]
[C08CA07, nisoldipine, Tolvaptan may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, The risk or severity of hyperkalemia can be increased when Nitrendipine is combined with Tolvaptan.]
[R07AX01, nitric oxide, Tolvaptan may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Tolvaptan may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Tolvaptan may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Tolvaptan may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Tolvaptan may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Tolvaptan.]
[G03DC02, norethindrone, The metabolism of Tolvaptan can be decreased when combined with Norethisterone.]
[C02KX01, bosentan, The metabolism of Tolvaptan can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Tolvaptan.]
[R05DA07, noscapine, The metabolism of Tolvaptan can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Tolvaptan can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, The risk or severity of hyperkalemia can be increased when Nylidrin is combined with Tolvaptan.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of Tolvaptan can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Tolvaptan can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Tolvaptan can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Tolvaptan can be increased when combined with Omeprazole.]
[N02AA02, opium, Tolvaptan may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[G04CA02, tamsulosin, Tolvaptan may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CF04, oxacillin, Tolvaptan may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Tolvaptan may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, The risk or severity of hyperkalemia can be increased when Oxprenolol is combined with Tolvaptan.]
[N02AA05, oxycodone, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Tolvaptan.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Danaparoid.]
[N02AX06, tapentadol, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Tapentadol.]
[J04AB30, capreomycin, Tolvaptan may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB05, paramethasone, The metabolism of Tolvaptan can be increased when combined with Paramethasone.]
[G04BD11, fesoterodine, Tolvaptan may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, Tolvaptan may increase the excretion rate of Penbutolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Tolvaptan may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Tolvaptan can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Tolvaptan may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AD03, pentoxifylline, Tolvaptan may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Perhexiline is combined with Tolvaptan.]
[N02AD02, phenazocine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Tolvaptan may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Tolvaptan may increase the excretion rate of Phenelzine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA02, phenobarbital, The metabolism of Tolvaptan can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Phenoperidine.]
[V03AB36, phentolamine, Tolvaptan may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The metabolism of Tolvaptan can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Tolvaptan can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Tolvaptan can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Tolvaptan may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BB03, bicalutamide, The metabolism of Tolvaptan can be decreased when combined with Bicalutamide.]
[B02BA01, vitamin K1, Tolvaptan may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Tolvaptan may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The serum concentration of Tolvaptan can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Tolvaptan can be decreased when combined with Pimozide.]
[C07AA03, pindolol, Tolvaptan may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA12, piperacillin, Tolvaptan may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The metabolism of Tolvaptan can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Tolvaptan may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Eprosartan.]
[N02AC03, pirinitramide, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, Tolvaptan may increase the excretion rate of Piroxicam which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG02, delavirdine, The metabolism of Tolvaptan can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Irbesartan.]
[A10BG02, rosiglitazone, Tolvaptan may increase the excretion rate of Rosiglitazone which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Polyethylene glycol.]
[L04AC08, canakinumab, The metabolism of Tolvaptan can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Tolvaptan can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Tolvaptan may increase the excretion rate of Saxagliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA01, potassium chloride, Tolvaptan may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Tolvaptan.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Tolvaptan.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Practolol is combined with Tolvaptan.]
[S03BA02, prednisolone, The metabolism of Tolvaptan can be increased when combined with Prednisolone.]
[H02AB07, prednisone, Tolvaptan may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Prenylamine is combined with Tolvaptan.]
[P01BA03, primaquine, The metabolism of Tolvaptan can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Tolvaptan can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Tolvaptan can be increased when combined with Probenecid.]
[C01BA02, procainamide, Tolvaptan may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AB05, fenofibrate, The metabolism of Tolvaptan can be decreased when combined with Fenofibrate.]
[R06AD02, promethazine, Tolvaptan may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, The serum concentration of Tolvaptan can be increased when it is combined with Propafenone.]
[A03AB05, propantheline, Tolvaptan may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX26, fexofenadine, The serum concentration of Tolvaptan can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The serum concentration of Tolvaptan can be increased when it is combined with Romidepsin.]
[N01AX10, propofol, The metabolism of Tolvaptan can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Tolvaptan can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Tolvaptan may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC04, rizatriptan, Tolvaptan may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Tolvaptan may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX07, dalfampridine, Tolvaptan may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Tolvaptan may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Tolvaptan may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Tolvaptan.]
[C01BA01, quinidine, The serum concentration of Tolvaptan can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Tolvaptan can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, Tolvaptan may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, Tolvaptan may increase the hyperkalemic activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Tolvaptan can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Tolvaptan may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, The serum concentration of Tolvaptan can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Tolvaptan can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Tolvaptan.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Tolvaptan.]
[N05CA06, secobarbital, The metabolism of Tolvaptan can be increased when combined with Secobarbital.]
[B05XA03, sodium chloride, The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan.]
[A12CD01, sodium fluoride, Tolvaptan may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[H01CB01, somatostatin, The metabolism of Tolvaptan can be decreased when combined with Somatostatin.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Tolvaptan.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Tolvaptan.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tolvaptan.]
[N05CC01, chloral hydrate, Tolvaptan may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AG01, valproic acid, The metabolism of Tolvaptan can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Tolvaptan can be increased when combined with Hydrocortisone butyrate.]
[C01DA14, isosorbide mononitrate, Tolvaptan may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA04, levoketoconazole, The metabolism of Tolvaptan can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Tolvaptan may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
